Cantor Fitzgerald reaffirmed their overweight rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report released on Monday, Benzinga reports. The brokerage currently has a $107.00 price target on the stock. Several other research firms also recently issued reports on AXSM. Bank of America raised Axsome Therapeutics from a neutral rating to […]

HC Wainwright restated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT – Free Report) in a report published on Monday, Benzinga reports. They currently have a $20.00 price objective on the stock. Checkpoint Therapeutics Stock Performance Shares of NASDAQ:CKPT opened at $2.46 on Monday. Checkpoint Therapeutics has a 52 week low of $1.30 and […]

HC Wainwright reiterated their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS – Free Report) in a research report report published on Monday, Benzinga reports. HC Wainwright currently has a $46.00 price target on the stock. Several other research firms have also recently commented on ITOS. Wells Fargo & Company began coverage on shares of […]

HC Wainwright reaffirmed their buy rating on shares of Cidara Therapeutics (NASDAQ:CDTX – Free Report) in a report issued on Monday morning, Benzinga reports. They currently have a $24.00 price target on the biotechnology company’s stock. A number of other brokerages also recently commented on CDTX. Needham & Company LLC reiterated a buy rating and […]

Cantor Fitzgerald reissued their neutral rating on shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) in a research note released on Monday, Benzinga reports. The firm currently has a $50.00 price objective on the biopharmaceutical company’s stock. Several other research analysts have also recently weighed in on the company. Barclays increased their price objective on […]

Cantor Fitzgerald restated their overweight rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a research note released on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $116.00 price objective on the biopharmaceutical company’s stock. RARE has been the topic of several other reports. Canaccord Genuity Group reaffirmed a buy rating and […]